Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Al Collard who wrote (1247)	4/16/2002 8:10:00 AM
From: Al Collard	Read Replies (1) \| Respond to of 1321

QLT announces Visudyne(R) sales for first quarter of 2002 Strong Visudyne Sales Exceed Analysts' Expectations VANCOUVER, April 16 /CNW/ - QLT Inc. (NASDAQ:QLTI; TSE:QLT) today reported global Visudyne(R) (verteporfin) sales of approximately US$68.4 million (CAD$109.0 million) for the quarter ended March 31, 2002. This represents an increase of 42.5% over sales in the first quarter of 2001 and is ahead of analysts' expectations of US$66.5 million. QLT will release its full financial results on Tuesday, April 23, 2002, at 4:00 p.m. EST. "We are very pleased to report Visudyne sales for the quarter ahead of the Street's expectations," said Paul Hastings, QLT's president and chief executive officer. "This year is off to a good start and we reiterate our annual sales guidance of US$275-300 million by year end as the global Visudyne franchise continues to expand." Visudyne is now approved in 62 countries for predominantly classic AMD and in over 40 countries for extended indications including CNV due to pathologic myopia. In addition, submissions have been filed with regulatory agencies in the European Union, Canada, Australia and New Zealand for the occult form of AMD. Visudyne sales in the U.S. for the quarter were approximately US$43.0 million (CAD$68.6 million), representing 62.9% of total sales for the quarter. The remaining US$25.4 million (CAD$40.4 million) relates to sales in the rest of the world. QLT Inc. is a world leader in photodynamic therapy, a field of medicine utilizing light-activated drugs in the treatment of disease. QLT's innovative science has led to the development and commercialization of breakthrough treatments utilizing this technology for applications in ophthalmology and oncology and is exploring the potential in other diseases. For more information, you are invited to visit QLT's web site at www.qltinc.com. QLT Inc. will hold an analyst and institutional investor conference call to discuss third quarter results on Tuesday, April 23, at 4:30 p.m. EST (1:30 p.m. PST). The call will be broadcast live via the Internet at www.qltinc.com. A replay of the call will be available via the Internet and also via telephone at (416) 626-4100, access code 20517322. Visudyne(R) is a registered trademark of Novartis AG QLT Inc. is listed on The Nasdaq Stock Market under the trading symbol "QLTI" and on The Toronto Stock Exchange under the trading symbol "QLT." The financial results for Visudyne sales in this press release are preliminary and unaudited and are not a complete disclosure of our quarterly or annual financial results. Certain statements in this press release constitute "forward-looking statements" of QLT within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to anticipated levels of sales of Visudyne(R) and opportunities to expand the market for Visudyne, including the prospects of obtaining approval for the use of Visudyne for the occult form of AMD in the countries listed above. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ materially from any future results express or implied by such statements include, but are not limited to: the risk that future sales of Visudyne may be less than expected, our future operating results are uncertain and likely to fluctuate, currency fluctuations in our primary markets may impact our financial results, the outcome of the pending patent and securities litigation against us is uncertain and may be unfavorable, we are dependent on third-parties to commercialize Visudyne, uncertainty of and timing of pricing and reimbursement and approvals in expanded indications, including the occult form of AMD, may limit the future sales of Visudyne and other factors described in detail in QLT's Annual Information Form on Form 10-K, forthcoming quarterly reports on Form 10-Q and other filings with the U.S. Securities and Exchange Commission. Forward-looking statements are based on our current expectations and QLT is not obligated to update such information to reflect later events or developments.